Subscribe to our monthly Workers' Comprehensive e-newsletter.
Get the most important workers' comp news delivered to your inbox.
FDA Encourages Drug Developers to Focus on Buprenorphine Depot Products
A newly released draft guidance encourages the development of more sustained-release buprenorphine products.
WCRI Releases CompScope Benchmarks
In-depth reports for 16 different states examine medical payments, costs, duration of disability, and more.
Illinois Bill May Allow Patients to Trade Opioids for Marijuana
Senate Bill 336 passed with a 44-6 vote and is now headed to the House.
The Craze Over Kratom
Kratom continues to grow in popularity as a drug for pain and opioid withdrawal, despite concerns from the FDA, CDC and DEA.
Four Current and Near-Future Drug Trends Impacting Rx Management
In a special partner post with WorkCompWire, Healthesystems discusses developments in pain management, specialty drugs, and more.
Opioid Withdrawal Drug Closer to Approval
If approved, Lucemyra (lofexidine) would be the first non-opioid drug approved to treat the symptoms of opioid withdrawal.
Dr. Silvia Sacalis Discusses Value-Based Care with WorkCompWire
Healthesystems’ VP of Clinical Services discusses how workers’ comp is embracing a value-driven approach.
WCIRB Reports on Chronic Opioid Use and Weaning
A new study analyzes the characteristics of chronic opioid use claims, while also examining opioid weaning data.
PTSD Bills Gain Momentum in Workers’ Comp
A Florida bill was recently signed into law, and states such as Arizona, Utah, Connecticut, and Oregon may follow suit.
More States Embrace Closed Drug Formularies
Indiana and Kentucky signed off on formulary bills, while other states continue to make progress on their promised formularies.
Dr. Robert Goldberg to Speak at IRSG
Healthesystems’ Chief Medical Officer will present "Can Workers’ Comp Catch Up to the Rest of Healthcare?" at the 2018 IRSG Annual Conference.
FDA Approves New Opioid Prodrug, Apadaz
Apadaz oral tablets were approved for the short-term management of acute pain, at no more than 14 days of use.
Dr. Silvia Sacalis to Speak at National Rx Drug Abuse & Heroin Summit
Healthesystems' VP of Clinical Services will co-present Workers' Comp Opioid Use Trends and Effective Population Health Management.
Ohio BWC Reports Falling Levels of Opioid Dependence
The number of opioid-dependent injured workers in the Ohio workers' comp system fell 19% in 2017.
Air Ambulances: State v Federal Cost Control
Many states have attempted to implement fee schedules for air ambulances, but courts citing federal regulations have stricken them down.
State and City Lawsuits Continue to Mount Against Opioid Manufacturers
Forty-one states and over 200 cities and counties claim drug makers deceived patients and doctors regarding opioid safety and addiction risks.
Drug Recalls Impacting Comp
Senna Laxative bottles were found to contain NSAIDs, while 55 lots of compounded drugs face questionable sterility.
A visual depiction of how opioid side effects can cascade across the body.
Increased Abuse Among Anti-Diarrhea Drugs
When taken in excessive doses, the anti-diarrhea drug loperamide can mimic opioid euphoria, and toxicity events and deaths are on the rise.
State Legislatures Increase Action Against Opioid Epidemic
The passage of opioid action plans in Arizona, Tennessee, and Pennsylvania are the most recent additions to growing statewide efforts to curb the epidemic.
The Rise of the Gig Economy
In 2003, gig workers made up less than 5% of the workforce. Today, estimates vary between 8% and 40%, raising questions for comp.
FDA Continues to Shift Opioid Strategy
2018 may hold more opioid policy revisions and the approval of new, non-opioid pain medications.
Artificial Intelligence and Workers’ Comp
Machine learning aims to automate parts of claims management.
No End in Sight for the Opioid Epidemic?
Despite decreases in prescribing rates, the opioid epidemic claims more lives than ever before, partially due to synthetic formulations.
State and Federal Governments Clash Over Marijuana
The Department of Justice’s recent announcement may come to a head with the will of state governments and popular opinion.
March of the Millennials
By 2020, millennials will make up half the workforce, so how will they impact workers’ comp?
FDA Approves Once-Monthly Buprenorphine Injection
Sublocade has been approved as the first once-monthly injectable buprenorphine product for opioid use disorder.
Dr. Silvia Sacalis Discusses Specialty Drug Trends with WorkCompWire
Healthesystems’ VP of Clinical Services covers specialty drug trends in workers’ comp, weighing costs alongside potential clinical benefits to injured workers.
New Study Ties Medical Marijuana to Reduced Opioid Use
A study from the University of New Mexico is the newest piece of research to link medical marijuana programs to decreased opioid use.
2018: The Year of Telemedicine?
While certain states move forward with telemedicine legislation, the market continues to grow, signaling a potential boom.
New RxInformer Clinical Journal Now Available
The Winter 2017 edition of Healthesystems’ clinical journal covering trending and influential topics in workers’ compensation is now available online.
Rexista Denied FDA Approval Over Abuse-Deterrent Properties
The FDA found that the abuse-deterrent properties of Rexista (oxycodone hydrochloride) extended-release tablets were not scientifically valid enough for approval.
Dr. Robert Goldberg Speaks to WC Magazine on Formularies
Healthesystems’ Chief Medical Officer was recently interviewed by WC Magazine on the growing popularity of workers’ comp formularies and the upcoming California formulary.
NCCI Analyzes Virginia’s Impending Fee Schedule Implementation
House Bill 378, which will implement the first workers’ compensation fee schedule in Virginia, takes effect January 1, 2018.
WCRI Reports on New York Opioid Use
When compared to a 26-state median, New York dispensed opioids to fewer claims, but the average opioid pill count per opioid claim was significantly higher.
Healthesystems at NWCDC 2017 in Las Vegas
Healthesystems will exhibit in booth #3707 from December 6-7. Our Clinical Pharmacist, Dr. Britten Featherston, will also co-present an educational session.
FDA Approves Zilretta for Osteoarthritis Knee Pain
Zilretta (triamcinolone acetonide extended-release injectable suspension) has been approved to manage osteoarthritis knee pain for 12-week intervals.
Healthesystems Pharmacists Named Finalists for Comp Laude Awards
Jeanette Connelly, PharmD, and Cheryl Hayes, PharmD, MBA are up for a prestigious award in workers’ comp for their commitment to ensuring the safety and appropriateness of pharmacotherapy for injured workers.
Acupuncture in Workers’ Comp
More clinical organizations support acupuncture as an alternative therapy to reduce opioid use, as do systematic reviews.
Arkansas Formulary Updates
The formulary implementation date has been changed to January 1, 2018, and the latest draft includes new opioid regulations.
Dr. Sacalis to Speak at WCI Emerging Trends Seminar Series
Healthesystems’ VP of Clinical Services will co-present Advancing Your Return to Work Program at the Workers’ Compensation Institute’s (WCI) Emerging Trends Seminar Series.
FDA Designates MDMA a Breakthrough Therapy in PTSD
The FDA gave the go-ahead for methylenedioxymethamphetamine (MDMA), the primary ingredient for the party drug ecstasy, to move forward with Phase 3 trials in patients with post-traumatic stress disorder (PTSD).
Dr. Robert Goldberg Speaks to Risk & Insurance on Physician Dispensing
Healthesystems’ Chief Medical Officer spoke with Risk & Insurance magazine on how the workers’ comp industry has managed this trend.
Ohio BWC Reports Reduced Opioid Usage
In 2016, 44% fewer injured workers received opioids when compared to 2011.
California DWC Moves to Update MTUS
As the California formulary will be based on ACOEM treatment guidelines, the MTUS may soon move away from ODG.
NCCI State Advisory Forums Highlight State-Specific Issues
Thirty-six member states plan to release reports detailing various trends in workers’ compensation.
FDA Approves Two New Hepatitis C Drugs
Mavyret and Vosevi are both indicated to treat HCV genotypes 1-6 without cirrhosis or with mild cirrhosis.
Tate Rice: Use of Virtual Reality and Video Games in Physical Therapy
Healthesystems’ Director of Physical Medicine discusses virtual reality with IAIABC.
Shifting Physician Dispensing Patterns
WCRI reports that while physicians dispensing has decreased after legislative reform, spending remains high due to new prescribing patterns.
Missouri to Enact PDMP
Executive Order 17-18 will make Missouri the final state in the U.S. to enact a prescription drug monitoring program.
DEA Proposes Descheduling Naldemedine
The DEA has found that the opioid-induced constipation drug appears to have very low abuse potential.
Non-Opioid Pain Medication Gets Fast Track Designation
Tanezumab, a biologic currently in Phase 3 development for chronic low-back pain, may benefit from increased FDA communications.
Healthesystems at WCI Orlando
Healthesystems will exhibit in booth #914 from August 7-9, and our VP of Clinical Services, Dr. Silvia Sacalis, will join a panel presentation on opioid best practices.
CDC Vital Signs – Opioid Prescribing Still High, Differs by County
While opioid prescribing rates have declined over the last several years, MME per person has tripled since 1999.
Texas Aims to Close Compounding Loophole
The Division of Workers’ Compensation released an informal working draft of a rule change that would exclude compounds from the state formulary.
Polypharmacy: How Many Drugs is Too Many?
The cost and safety concerns of multiple simultaneous drug regimens.
FDA Requests Removal of Opana ER, Reexamines Abuse-Deterrent Opioids
After requesting a manufacturer remove the opioid Opana ER from the market, the FDA announced a public meeting to discuss the real-world impact of abuse-deterrent opioids.
How Off-Label Prescribing Drives a Claim Off Course
How can common forms of off-label prescribing impact claim costs and outcomes?
New York Workers’ Comp Formulary Update
The New York Workers’ Compensation Board has clarified a deadline for formulary selection and rule development, along with certain formulary requirements.
Illicit Opioid Use Linked to Hepatitis C
The CDC found that Hepatitis C infections tripled in the last five years due to drug use related to the opioid epidemic.
Dr. Silvia Sacalis Discusses the Need for Early Opioid Interventions
Healthesystems’ VP of Clinical Services spoke with Business Insurance on the importance of preventing opioid misuse to avoid long-term complications.
FDA Approves New Opioid: RoxyBond
The FDA approved RoxyBond® (oxycodone hydrochloride) tablets for the treatment of pain for which alternative treatments are inadequate.
Not-So Science Fiction: Innovative Technologies in Workers’ Comp
Learn how brain-computer interface, exoskeletons, 3D printing and virtual reality can impact workers’ comp.
Utah Bill May Allow Insurers to Enforce Opioid Prescribing Policies
House Bill 90 went into effect May 9th, allowing group health and workers’ comp insurers to enforce evidence-based opioid prescribing policies.
Are Opioid-Related Deaths Underreported?
A CDC report ties several unexplained deaths in Minnesota to opioid use, indicating that more deaths nationwide could be opioid-related than previously thought.
WorkCompWire Interviews Daryl Corr
Healthesystems CEO, Daryl Corr, was recently featured in a “RIMS Review” by WorkCompWire, in which he discusses formularies, a more adherent healthcare model, and protecting data.
Symproic® Approved for Opioid-Induced Constipation
The FDA approved Symproic® (naldemedine) oral tablets for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
Future Opioids and the Injured Worker: Why “Safer” is a Relative Term
Drug makers are developing new opioids with potential safety improvements over old formulations, but do they fall short for injured workers?
New York to Enact Workers’ Comp Formulary
The passage of Assembly Bill A3009C calls for a workers’ comp formulary by 2018.
How Initial Opioid Use Impacts Long-Term Opioid Use
Data from 1.3 million patients reveals how early prescribing decisions can influence long-term opioid use.
Successful Speaking Events in Atlanta and Denver
Healthesystems clinical leaders recently presented at the National Rx Drug Abuse & Heroin Summit in Atlanta, Georgia, and at the American Occupational Health Conference in Denver, Colorado.
Olinvo (oliceridine) Completes Phase III Clinical Trials
An opioid developed to reduce adverse effects yielded lower rates of certain opioid-related side effects, but only in low drug doses.
Dr. Robert Goldberg Comments on Virtual Reality in Workers’ Comp
VR application in workers’ comp has great promise, but clinical guidelines are still years away.
Formularies Continue to Gain Steam
Pennsylvania, Kentucky, and Nebraska join the many states considering workers’ comp formularies.
ACP Releases Guideline for Chronic Low Back Pain
New guideline emphasizes non-pharmacologic treatments and alternative therapies.
Focus On: Opioid Overdose and Dependence Therapies
Claims considerations for the opioid-overdose drug naloxone, and the opioid-dependency drug buprenorphine.
FDA Approves Two New Opioids, New Dose for Narcan Nasal Spray
The FDA approved Arymo ER, Vantrela ER and a new 2mg dose of the opioid overdose reversal agent, Narcan.
Naloxone: The Path to Increased Patient Access
How has innovation and legislation impacted naloxone use?
Brain-Computer Interface: New Research
Providing mobility for paralyzed patients?
More State Limits on Opioid Prescriptions?
New Jersey, Utah, Indiana, Oregon and Maryland consider opioid prescription limits.
Compound Drug Trends in Florida
Compound spending has decreased as pharmacies dispense fewer compounds, but prescriber-dispensing continues to increase.
Manufacturers are working to develop opioids with fewer adverse effects.
Expect More State Formulary Action in 2017
Momentum behind state formularies will continue, especially as current data help inform what is working and what can be improved.
Incoming Exoskeleton Boom?
They work, they are expensive, and everyone wants to build them.
Mandatory PDMP Use
Legislation hints at a new trend, one that takes the effectiveness of PDMPs to a new level.
Telemedicine: Slowly But Surely
It’s been championed as a new tool for workers’ comp. But are there enough data on telemedicine to expect large-scale implementation?
Cantrell Drug Company Issues Voluntary Recall Due to Lack of Sterility Assurance
Common workers’ comp drugs impacted by the recall include fentanyl, hydromorphone, morphine sulfate, and lidocaine.
Using Multidimensional Data to Estimate Potential Opioid Misuse
Analyzing multidimensional data across a broad patient population can reveal hidden risk factors for opioid misuse.
Department of Health and Human Services Expands Buprenorphine Access
Nurse practitioners and physician assistants will soon be able to prescribe the opioid dependence drug buprenorphine for up to 30 patients.
California DWC Formulary Webinar
Dr. Robert Goldberg, Healthesystems’ chief medical officer, will host an educational webinar for WOEMA on Wednesday, December 21 at 12:00 PM PT.
What Should Claims Professionals Know About Therapeutic Duplication?
The prescribing of multiple medications for the same indication can lead to serious safety and cost concerns.
New Evzio Strength Approved
The FDA approved a new 2 mg strength of Evzio (naloxone hydrochloride) auto-injector for the emergency treatment of opioid overdose.
Compound Medications: A Formula for Disaster
Often prescribed to treat pain associated with workplace injury, compounds are less regulated than FDA-approved drugs, resulting in significant patient safety and cost concerns.
WCRI Measures Opioid Use Between States
States with closed drug formularies and strong PDMP usage saw decreases in opioids per claim.
New York Expresses Interest in Workers' Comp Drug Formulary
The New York Workers' Compensation Board (WCB) announced their intent to establish a workers' comp prescription drug formulary.
Connect with Healthesystems at NWCDC 2016 in New Orleans
As proud gold sponsors of NWCDC 2016, Healthesystems invites you to visit us at booth 1419, and to attend one of our speaking sessions.
FDA Approves Biosimilar Amjevita
The FDA approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.
Don't Overlook the Impact of Age and Comorbidity
With the number of claims including a comorbidity almost tripling in the last decade, how do comorbid conditions impact pharmacy management in the injured worker?
Ohio BWC Limits Opioid Reimbursements
Effective October 1st, the Ohio Bureau of Workers\' Compensation will only reimburse opioid prescriptions that adhere to best medical practices.
DEA Reduces Opioid Manufacturing Quotas for 2017
Schedule I and II drugs will see manufacturing quotas drop by 25% or more for 2017.
Dr. Goldberg Comments on California PDMP Law
Dr. Robert Goldberg, Chief Medical Officer, spoke with WorkCompCentral on California's new law requiring prescribers to consult the state prescription drug monitoring program before prescribing Schedule II-IV drugs.
FDA Approves New Opioid: Troxyca ER
The FDA approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for severe pain. The new product has been labeled as abuse-deterrent.
Medically Speaking: Marijuana and Pain Management
With state and federal legislation expanding the use and research of medical marijuana, what does the data say about marijuana and pain?
NCCI Reports on Prescription Drug Costs in Workers' Comp
A new update by NCCI shows prescription drug spending comprises 17% of total workers' comp medical costs, despite decreased utilization.
California DWC Releases Draft Formulary Regulations
The formulary seeks to improve quality of care, and to reduce frictional costs and the cost of prescription drugs.
Dr. Sacalis to Speak at CWC & Risk Conference
Dr. Silvia Sacalis, VP of Clinical Services, will co-present Integration Is the Key to Managing Claim Complexities at the CWC & Risk Conference.
FDA Approves Relistor Tablets for Opioid-Induced Constipation
The FDA approved Relistor tablets (methylnaltrexone bromide) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
Gender Considerations in Workers' Compensation
Do women face increased risks with prescription pain medications?
Impacts of Physician Dispensing Reforms
New cost drivers have emerged to offset savings from state-wide physician dispensing reforms, according to WCRI.
New State Opioid Limits
New York passed A10727, limiting initial opioid prescriptions for acute pain to a seven-day supply, joining other states that have enacted similar laws.
Topical Convenience Packs
Low-cost drug products face severe and unnecessary increases in price when they are packaged together in convenience packs, often with no medical benefit.